AGEN:NSC-Agenus Inc. (USD)

EQUITY | Biotechnology | NASDAQ Capital Market

Last Closing

USD 0.58

Change

+0.02 (+4.24)%

Market Cap

USD 0.41B

Volume

5.51M

Analyst Target

USD 8.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Agenus Inc along with its subsidiaries is an immuno-oncology company. The Company is engaged in iscovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 102.73B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 96.94B
MRNA Moderna Inc

N/A

USD 38.83B
ARGX argenx NV ADR

N/A

USD 22.16B
BNTX BioNTech SE

N/A

USD 21.93B
GMAB Genmab AS

N/A

USD 18.26B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 18.12B
RPRX Royalty Pharma Plc

N/A

USD 16.73B
BGNE BeiGene Ltd

N/A

USD 16.68B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.35B

ETFs Containing AGEN

RCRS:XETRA Rize UCITS ICAV - Rize Cy.. 4.73 % 0.00 %

N/A

USD 0.13B
RCRS:F Rize UCITS ICAV - Rize Cy.. 4.73 % 0.00 %

N/A

USD 0.13B
USPY:XETRA L&G Cyber Security UCITS .. 4.48 % 0.00 %

N/A

USD 2.62B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.12% 17% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.12% 17% F 13% F
Trailing 12 Months  
Capital Gain -60.00% 23% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.00% 23% F 15% F
Trailing 5 Years  
Capital Gain -80.47% 38% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -80.47% 38% F 14% F
Average Annual (5 Year Horizon)  
Capital Gain -11.54% 45% F 26% F
Dividend Return -11.54% 45% F 25% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 41.24% 66% D+ 43% F
Risk Adjusted Return -27.97% 43% F 28% F
Market Capitalization 0.41B 57% F 51% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 8.20 47% 75%
Price/Book Ratio 218.61 1% 0%
Price / Cash Flow Ratio -1.04 34% 60%
Price/Free Cash Flow Ratio -1.61 53% 65%
Management Effectiveness  
Return on Equity -1,278.83% 5% 2%
Return on Invested Capital 151.82% 95% 98%
Return on Assets -27.51% 57% 19%
Debt to Equity Ratio -7.96% 77% 89%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.